-
Notifications
You must be signed in to change notification settings - Fork 4
Seroprevalence
A public repository of scientific and media resources of SARS-CoV-2 related COVID-19 maintained by ITER.
Section to show information on Seroprevalence and related on going studies.
A case of a readmitted patient who recovered from COVID-19 in Chengdu, China
A serological assay to detect SARS-CoV-2 seroconversion in humans
A serological assay to detect SARS-CoV-2 seroconversion in humans
Considering how biological sex impacts immune responses and COVID-19 outcomes
Coronavirus: los primeros datos de seroprevalencia estiman que un 5% de la población ha estado contagiada, con variabilidad según provincias | INFORME
COVID-19 and Postinfection Immunity. Limited Evidence, Many Remaining Questions
COVID-19 Antibody Seroprevalence in Santa Clara County, California
Daily viral kinetics and innate and adaptive immune responses assessment in COVID-19: a case series
Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals
Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis
Disappearance of antibodies to SARS-CoV-2 in a Covid-19 patient after recovery
Dissecting antibody-mediated protection against SARS-CoV-2
Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants
Estimation of SARS-CoV-2 infection fatality rate by real-time antibody screening of blood donors
Estimating population immunity without serological testing
Humoral Response Dynamics Following Infection with SARS-CoV-2
Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection
Immune evasion via SARS-CoV-2 ORF8 protein?
Longitudinal analyses reveal immunological misfiring in severe COVID-19
Long-Term Persistence of IgG Antibodies in SARS-CoV Infected Healthcare Workers
Pre-existing immunity to SARS-CoV-2: the knowns and unknowns
Presence of SARS-CoV-2 reactive T cells in COVID-19 patients and healthy donors
Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19
SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19
SARS-CoV-2 seroprevalence in COVID-19 hotspots
Test performance evaluation of SARS-CoV-2 serological assays
The potential danger of suboptimal antibody responses in COVID-19
Towards the next phase: evaluation of serological assays for diagnostics and exposure assessment
By JMLS @resocios ![]()